Current Rating Overview
MarketsMOJO currently assigns Medico Remedies Ltd a 'Hold' rating, reflecting a balanced outlook on the stock. This rating indicates that the stock is expected to perform in line with the broader market and sector averages, suggesting neither a strong buy nor a sell stance at present. The Mojo Score supporting this rating stands at 52.0, a moderate improvement from the previous score of 47, signalling a modest enhancement in the company’s overall profile.
Quality Assessment
As of 21 May 2026, Medico Remedies demonstrates a solid quality grade, underpinned by efficient management and robust profitability metrics. The company boasts a high Return on Capital Employed (ROCE) of 15.04%, indicating effective utilisation of capital to generate earnings. Furthermore, the latest half-year data reveals an even stronger ROCE of 20.65%, highlighting improved operational efficiency in recent months. The company’s ability to consistently declare positive results over the last four consecutive quarters further reinforces its quality credentials.
Valuation Perspective
Currently, the valuation grade for Medico Remedies is assessed as fair. The stock trades at an Enterprise Value to Capital Employed ratio of 5.1, which is considered reasonable within its sector. Notably, the stock is priced at a discount relative to its peers’ historical valuations, offering potential value for investors seeking exposure to the Pharmaceuticals & Biotechnology sector. The company’s Price/Earnings to Growth (PEG) ratio stands at 1.1, suggesting that the stock’s price is fairly aligned with its earnings growth prospects.
Financial Trend Analysis
The financial trend for Medico Remedies is positive, reflecting encouraging growth in profitability and operational metrics. The company’s Profit After Tax (PAT) for the latest six months is ₹5.44 crores, representing a robust growth rate of 30.46%. Additionally, Profit Before Tax excluding other income (PBT less OI) for the quarter has surged by 52.17%, signalling strong core business performance. The company maintains a low Debt to EBITDA ratio of 0.82 times, indicating prudent leverage and a strong capacity to service debt obligations.
Technical Outlook
From a technical standpoint, the stock currently exhibits a mildly bearish trend. Despite short-term fluctuations, the stock has shown resilience with a 1-month gain of 12.63% and a 1-week increase of 5.65%. However, longer-term returns have been subdued, with a 6-month decline of 9.96% and a year-to-date drop of 9.02%. Over the past year, the stock has underperformed the broader market, delivering a negative return of 17.55% compared to the BSE500’s modest decline of 0.60%. This divergence suggests that while fundamentals are improving, market sentiment remains cautious.
Stock Performance Summary
As of 21 May 2026, Medico Remedies Ltd’s stock price has experienced mixed performance across various time frames. The stock gained 0.63% on the most recent trading day, reflecting some positive momentum. Over the past month, the stock appreciated by 12.63%, indicating short-term strength. Conversely, the 3-month return is nearly flat at -0.07%, and the 6-month and year-to-date returns remain negative at -9.96% and -9.02%, respectively. The one-year return of -17.55% highlights the stock’s underperformance relative to the broader market and sector indices.
Investor Implications of the Hold Rating
The 'Hold' rating suggests that investors should maintain their current positions in Medico Remedies Ltd without initiating new purchases or sales based solely on the present outlook. The company’s improving fundamentals and fair valuation provide a stable foundation, but the mildly bearish technical signals and recent underperformance caution against aggressive accumulation. Investors may consider monitoring the stock for further developments in financial trends and technical indicators before making significant portfolio adjustments.
Company Profile and Shareholding
Medico Remedies Ltd operates within the Pharmaceuticals & Biotechnology sector and is classified as a microcap company. The majority shareholding is held by promoters, which often indicates stable ownership and potential alignment with shareholder interests. The company’s focus on delivering consistent profitability and managing debt prudently positions it well for navigating sector challenges and capitalising on growth opportunities.
Fast mover alert! This Large Cap from Automobiles - Passeenger just qualified for our Momentum list with stellar technical indicators. Strike while the iron is hot!
- - Recent Momentum qualifier
- - Stellar technical indicators
- - Large Cap fast mover
Summary and Outlook
In summary, Medico Remedies Ltd’s current 'Hold' rating by MarketsMOJO reflects a nuanced view of the company’s prospects. The stock benefits from strong management efficiency, positive financial trends, and a fair valuation relative to peers. However, the mildly bearish technical outlook and recent underperformance relative to the broader market temper enthusiasm. Investors should weigh these factors carefully, recognising that the stock currently offers a balanced risk-reward profile.
Looking ahead, continued improvement in profitability metrics and a shift towards more positive technical signals could prompt a reassessment of the rating. For now, maintaining existing holdings while monitoring market developments appears prudent.
Key Metrics at a Glance (As of 21 May 2026)
- Mojo Score: 52.0 (Hold)
- ROCE: 15.04% (Latest Half Year: 20.65%)
- Debt to EBITDA: 0.82 times
- PAT Growth (6 months): 30.46%
- PBT less Other Income Growth (Quarterly): 52.17%
- Enterprise Value to Capital Employed: 5.1
- PEG Ratio: 1.1
- 1-Year Stock Return: -17.55%
- BSE500 1-Year Return: -0.60%
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
